Furthermore, a 3D drug screening proof-of-concept showed high-quality reproducibility between CRC organoids (n = 18) with their genomic features and drug sensitivity, favoring the identification of useful genetic markers to predict drug resistance in CRC patients (for example KRAS and TP53 wild-type organoids were sensitive to cetuximab and Nutlin-3a [40]. The gene discussed is KRAS; the disease is colorectal carcinoma.